丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果

Clinical effect of Sodium Tanshinone ⅡA Sulfonate Injection in the treatment of senile pulmonary heart disease

目的探讨丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果。方法选取2013年6月~2015年6月在首都医科大学附属北京潞河医院就诊的肺心病急性加重期老年患者86例。按随机数字表法将其分为对照组和观察组,每组各43例。两组均给予常规治疗,观察组则在常规治疗的基础上给予静脉滴注丹参酮ⅡA磺酸钠注射液。观察两组患者临床疗效,比较两组患者治疗前后血液流变学各项指标、动脉血气分析及肺动脉收缩压,记录两组患者治疗过程中有无不良反应发生。结果观察组总有效率(88.37%)明显高于对照组(76.74%),差异有统计学意义(P<0.05)。治疗后,两组患者各项血液流变学指标(全血高切黏度、全血低切黏度、血浆黏度、血细胞比容、红细胞聚集指数、血小板聚集率、纤维蛋白原)均明显低于治疗前,差异有统计学意义(P<0.05);治疗后,观察组患者上述各项血液流变学指标明显低于对照组,差异有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后动脉氧分压(Pa O2)显著上升,动脉血二氧化碳分压(Pa CO_2)及肺动脉收缩压均显著降低,差异均有统计学意义(P<0.05)。治疗后,观察组患者Pa O_2显著高于对照组,Pa CO_2及肺动脉收缩压均显著低于对照组,差异有统计学意义(P<0.05)。两组患者治疗过程中均未见明显不良反应。结论丹参酮ⅡA磺酸钠注射液治疗老年肺心病患者效果显著,其能有效减轻患者的临床症状、体征,提高心功能,改善血液流变学和肺动脉高压状态,且安全性高,值得临床推广应用。

Objective To investigate the clinical effect of Sodium Tanshinone Ⅱ A Sulfonate Injection in the treatment of senile pulmonary heart disease. Methods Eighty-six cases of elderly patients with acute stage of pulmonary heart disease treated in Beijing Luhe Hospital, Capital Medical University from June 2013 to June 2015 were selected and divided into control group and observation group by random number table method, with 43 cases in each group. Both groups were given conventional treatment, on basis of which, the observation group was added with Sodium Tanshinone Ⅱ A Sulfonate Injection, intravenous drip. The clinical effect of the two groups was observed, the indexes of hemorheology, arterial blood gas analysis, pulmonary artery systolic pressure of the two groups before and after treatment were compared, the adverse reactions of the two groups during the course of treatment were recorded. Results The total ef- fective rate of observation group （88.37%） was higher than that of control group （76.74%）, the difference was statistically significant （P 〈 0.05）. After treatment, the indexes of hemorheology （whole high blood viscosity, whole low blood viscosity, plasma viscosity, hematocrit, red cell assembling index, platelet aggregation rate, fibrinogen） in the two groups were all lower than those before treatment, the differences were statistically significant （P 〈 0.05）; after treatment, the indexes of hemorheology above in the observation group were all lower than those of control group, the differences were statistically significant （P 〈 0.05）. Compared with before treatment, the PaO2 of the two groups after treatment were increased, PaCO2 and pulmonary artery systolic pressure were decreased, the differences were statistically significant （P 〈 0.05）. After treatment, the PaO2 of observation group was higher than that of control group, the PaCO2 and pulmonary artery systolic pressure were lower than those of control group, the differences were statistically significant （P 〈 0.05）. Both groups had no obvious adverse reactions during the treatment. Conclusion Sodium Tanshinone Ⅱ A Sulfonate Injection in the treatment of senile pulmonary heart disease has significant effects, which can reduce the clinical signs and symptoms, improve the cardiac function and the states of hemorheology and pulmonary arterial hypertension, and the safety is high, which is worthy of clinical promotion and application.